HANSA BIOPHARMA AB SK 1 revenue breakdown overview

HANSA BIOPHARMA AB SK 1 revenue for the last year amounted to 11.99 M EUR, the most of which — 11.99 M EUR — came from its highest performing source at the moment, Antibody-cleaving Enzyme Technology Platform, the year earlier bringing 13.79 M EUR. The greatest contribution to the revenue figure was made by Europe (excluding Sweden) — last year it brought HANSA BIOPHARMA AB SK 1 9.54 M EUR, and the year before that — 7.64 M EUR.